Biotech company Ignyta just put itself on the map in a big way after announcing stellar phase 1 results for its lead cancer drug. Still, investors would be wise to keep a few other important things in mind before getting too excited.
Biotech company Ignyta just put itself on the map in a big way after announcing stellar phase 1 results for its lead cancer drug. Still, investors would be wise to keep a few other important things in mind before getting too excited.